FDA Grants Priority Review to Atezolizumab to Treat Advanced Non-Small Cell Lung Cancer

Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.

Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news